Sentence examples for pharmaceutical assessment from inspiring English sources

The HTA process, as commonly applied to conventional drug evaluation, should upgrade to a full pharmaceutical assessment, considering the DDS complexity.

This chapter discusses challenges and issues with quality by testing (QbT) and the old pharmaceutical assessment system, and also introduces the concepts and understanding of quality by design (QbD) for generic drugs.

We draw out the expertise necessary to perform the pharmaceutical assessment and we propose a format to evaluate the DDS technological topics such as formulation and mechanism of action, physicochemical characteristics, manufacturing process.

Not all participants were familiar with the Named Patient Pharmaceutical Assessment (NPPA) iv access scheme.

We used the Pharmaceutical Assessment and Transport Evaluation (P hATE) model to predict concentrations of estrogens potentially present in drinking water.

The predicted environmental concentrations (PECs) of synthetic estrogens and endogenous estrogens in drinking water resulting from human use and excretion were estimated using the P hATE (Pharmaceutical Assessment and Transport Evaluation) model, version 2.1.1 (Anderson et al. 2004).

Opening a new community pharmacy can be a complex process, as new applications made to NHS England are assessed against a Pharmaceutical Needs Assessment for a particular area 30 with areas of the most need having a higher probability of a new application being granted.

Toxicokinetic (TK) information can substantially enhance the value of the data generated from toxicity testing, and is an integral part of pharmaceutical safety assessment.

The aim of this paper is to propose a pharmaceutical risk assessment strategy that goes beyond the usual characterisation of a clinical candidate molecule according to the biopharmaceutical classification system (BCS).

The most recent national data on prescribing indicators available for comparison was the pharmaceutical situation assessment carried out in May/June 2008 [ 30].

The FDA's ultimate goal was to transform its CMC review practices into a science and risk-based pharmaceutical quality assessment system which could potentially lead to an increase in the number of successful new applications and a reduction in the number of post-approval supplements.